Holen Sie sich die Stockscreener-App
1.18
4.84%
-0.06
Vorhandelsmarkt:
1.19
0.01
+0.85%
Schlusskurs vom Vortag:
$1.24
Offen:
$1.25
24-Stunden-Volumen:
2.09M
Relative Volume:
0.57
Marktkapitalisierung:
$261.82M
Einnahmen:
$95,000
Nettoeinkommen (Verlust:
$-327.27M
KGV:
-0.5566
EPS:
-2.12
Netto-Cashflow:
$-239.25M
1W Leistung:
-4.07%
1M Leistung:
-11.28%
6M Leistung:
-30.59%
1J Leistung:
-56.62%
1-Tages-Spanne:
$1.17
$1.26
1-Wochen-Bereich:
$1.17
$1.31
52-Wochen-Spanne:
$0.8621
$3.78
Allogene Therapeutics Inc Stock (ALLO) Company Profile
Firmenname
Allogene Therapeutics Inc
Sektor
Branche
Telefon
(650) 457-2700
Adresse
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Vergleichen Sie ALLO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
1.18 | 275.13M | 95,000 | -327.27M | -239.25M | -2.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-05-14 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-08-08 | Fortgesetzt | Oppenheimer | Outperform |
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
| 2024-01-05 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-01-05 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-08 | Eingeleitet | Citigroup | Buy |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-01-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-01-06 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-12-12 | Herabstufung | BofA Securities | Buy → Underperform |
| 2022-08-10 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-07-15 | Hochstufung | Goldman | Neutral → Buy |
| 2022-06-03 | Eingeleitet | Robert W. Baird | Neutral |
| 2022-02-28 | Bestätigt | B. Riley Securities | Buy |
| 2021-10-20 | Eingeleitet | Cowen | Outperform |
| 2021-10-08 | Herabstufung | Goldman | Buy → Neutral |
| 2021-10-08 | Herabstufung | Stifel | Buy → Hold |
| 2021-09-23 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2021-06-21 | Fortgesetzt | Jefferies | Buy |
| 2021-05-20 | Hochstufung | Truist | Hold → Buy |
| 2021-05-14 | Eingeleitet | B. Riley Securities | Buy |
| 2021-01-26 | Hochstufung | Stifel | Hold → Buy |
| 2020-12-10 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-11-24 | Eingeleitet | BofA Securities | Buy |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-06-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-29 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-19 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2020-05-15 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-05-14 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-14 | Herabstufung | SunTrust | Buy → Hold |
| 2020-04-13 | Eingeleitet | SunTrust | Buy |
| 2020-03-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-05 | Eingeleitet | Stifel | Hold |
| 2020-02-24 | Eingeleitet | Berenberg | Hold |
| 2019-12-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2019-11-04 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-06-05 | Eingeleitet | ROTH Capital | Neutral |
| 2019-05-31 | Eingeleitet | Guggenheim | Neutral |
| 2019-05-23 | Eingeleitet | Stifel | Hold |
| 2019-03-29 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Allogene Therapeutics Inc Aktie (ALLO) Neueste Nachrichten
How sentiment analysis helps forecast Allogene Therapeutics Inc.2025 Market WrapUp & Stepwise Trade Signal Guides - newser.com
Allogene to present pivotal trial design for lymphoma therapy at ASH - Investing.com Nigeria
Will Allogene Therapeutics Inc. stock deliver better than expected guidanceJuly 2025 Price Swings & Accurate Intraday Trading Signals - newser.com
Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting - The Manila Times
Allogene to present pivotal trial design for lymphoma therapy at ASH By Investing.com - Investing.com South Africa
Why Allogene Therapeutics Inc. stock remains on watchlistsQuarterly Performance Summary & Consistent Return Investment Signals - newser.com
Will Allogene Therapeutics Inc. stock remain a Wall Street favoriteJuly 2025 Intraday Action & AI Enhanced Execution Alerts - newser.com
Analyzing Allogene Therapeutics Inc. with multi timeframe chartsJuly 2025 Trends & Community Verified Trade Signals - newser.com
Using AI based signals to follow Allogene Therapeutics Inc.Profit Target & Free Growth Oriented Trading Recommendations - newser.com
Published on: 2025-11-02 23:31:58 - newser.com
Will breakout in Allogene Therapeutics Inc. lead to full recoveryWeekly Market Report & High Accuracy Investment Signals - newser.com
Chart based analysis of Allogene Therapeutics Inc. trends2025 Top Decliners & Daily Profit Focused Screening - newser.com
Using portfolio simulators with Allogene Therapeutics Inc. includedJuly 2025 Big Picture & Risk Managed Investment Entry Signals - newser.com
Price action breakdown for Allogene Therapeutics Inc.Earnings Overview Report & AI Powered Trade Plan Recommendations - newser.com
Risk adjusted return profile for Allogene Therapeutics Inc. analyzedPortfolio Growth Summary & AI Driven Stock Reports - newser.com
Applying Elliott Wave Theory to Allogene Therapeutics Inc.Quarterly Portfolio Report & Consistent Profit Trading Strategies - newser.com
Published on: 2025-11-02 02:58:33 - newser.com
What candlestick patterns are forming on Allogene Therapeutics Inc.Chart Signals & Community Trade Idea Sharing Platform - newser.com
Detecting support and resistance levels for Allogene Therapeutics Inc.July 2025 WrapUp & AI Forecast for Swing Trade Picks - newser.com
Allogene Therapeutics (ALLO) to Release Quarterly Earnings on Thursday - MarketBeat
Allogene Therapeutics (NASDAQ: ALLO) sets Q3 2025 results; webcast at 2 p.m. PT - Stock Titan
Will Allogene Therapeutics Inc. stock beat EPS estimatesEarnings Risk Report & Free Growth Oriented Trading Recommendations - Fundação Cultural do Pará
Finanzdaten der Allogene Therapeutics Inc-Aktie (ALLO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):